Evolus, Inc.
NASDAQ:EOLSDrug Manufacturers - Specialty & Generic
-$0.14 today
- Market cap
- $467.95M
- Beta
- 1.33
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$0.67
Volume 0.80M
Average 0.86M
EOLS Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Evolus, Inc.NASDAQ: EOLS
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) grows in line with its trailing trend
Q1 FY2026 weighted avg shares (diluted) of 65.19M shares rose 2.3% year over year, in line with the +2.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +2.3% toward the trailing-twelve-month pace of +2.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 64.47M USD
- Year-over-year change
- +4.0%
- 4-year CAGR
- +6.7%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.47M | +4.0% |
| FY2024 | 2024-12-31 | 62.02M | +9.0% |
| FY2023 | 2023-12-31 | 56.92M | +1.5% |
| FY2022 | 2022-12-31 | 56.07M | +12.6% |
| FY2021 | 2021-12-31 | 49.77M | — |
Weighted Avg Shares (Diluted) vs competitors
How EOLS compares with its peers on the latest reported figures
No competitor Weighted Avg Shares (Diluted) figures are available to compare.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 99.67M | 148.62M | 202.09M | 266.27M | 297.18M |
| Cost of Revenue | 43.53M | 58.84M | 61.56M | 83.97M | 104.41M |
| Gross Profit | 56.14M | 89.77M | 140.53M | 182.3M | 192.76M |
| Gross Margin | 56.3% | 60.4% | 69.5% | 68.5% | 64.9% |
| Research & Development | 2.06M | 6.74M | 15.43M | 9.17M | 9.58M |
| Selling, General & Admin | 112.07M | 141.84M | 164.94M | 198.03M | 220.79M |
| Operating Expenses | 100.54M | 155.1M | 189.76M | 216.72M | 230.36M |
| Depreciation & Amortization | 6.31M | 3.72M | 5.87M | 6.02M | 8.74M |
| EBITDA | (39.06M) | (53.85M) | (41.81M) | (25M) | (22.53M) |
| EBITDA Margin | -39.2% | -36.2% | -20.7% | -9.4% | -7.6% |
| Operating Income | (44.41M) | (65.33M) | (49.23M) | (34.41M) | (37.6M) |
| Operating Margin | -44.6% | -44.0% | -24.4% | -12.9% | -12.7% |
| Interest Income | 1K | 119K | 860K | 3.26M | 1.93M |
| Interest Expense | 1.4M | 9.1M | 13.83M | 18.74M | 19.69M |
| Other Income / Expenses | (2.36M) | (8.99M) | (12.28M) | (15.35M) | (13.36M) |
| Income Before Tax | (46.77M) | (74.32M) | (61.51M) | (49.76M) | (50.96M) |
| Pre-Tax Margin | -46.9% | -50.0% | -30.4% | -18.7% | -17.1% |
| Income Tax Expense | 42K | 95K | 176K | 664K | 677K |
| Net Income | (46.81M) | (74.41M) | (61.69M) | (50.42M) | (51.64M) |
| Net Margin | -47.0% | -50.1% | -30.5% | -18.9% | -17.4% |
| EPS (Basic) | (0.94) | (1.33) | (1.08) | (0.81) | (0.80) |
| EPS (Diluted) | (0.94) | (1.33) | (1.08) | (0.81) | (0.80) |
| Weighted Avg Shares | 49.77M | 56.07M | 56.92M | 62.02M | 64.47M |
| Weighted Avg Shares (Diluted) | 49.77M | 56.07M | 56.92M | 62.02M | 64.47M |
Evolus, Inc.
NASDAQ:EOLS
Intrinsic Alpha fair value
Locked
Current Price
$7.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.